Duality Biologics Fuels the Future of ADC Therapeutics with a $194M Funding Boost

In a major milestone for innovative biopharmaceutical research, Duality Biologics, a clinical-stage company specializing in next-generation ADC therapeutics, has successfully raised $194 million in funding. This significant capital infusion underscores the company’s robust vision and pioneering approach in the field of targeted therapies for patients suffering from cancer and autoimmune diseases. With a proven track record in establishing cutting-edge Antibody-Drug Conjugate (ADC) technology platforms, each protected by global intellectual property rights, Duality Biologics leverages a deep understanding of disease biology to transform groundbreaking research into transformative clinical solutions. The fresh funding will be strategically directed towards accelerating the development of its extensive pipeline. Currently, the company is advancing four potent assets into global clinical studies while simultaneously nurturing more than ten innovative product candidates in its preclinical portfolio. Furthermore, this capital will enable further evolution of its novel protein engineering and ADC technology platforms, paving the way for the creation of the next wave of “super ADC” molecules. These initiatives include the development of therapies with diverse payload classes, bispecific ADCs, and dual payload ADCs that promise to deliver enhanced safety profiles and improved efficacy. By investing in both early-stage discovery and late-stage clinical validation, Duality Biologics is positioning itself at the forefront of innovation, fostering collaborations with multinational pharmaceutical companies, and expanding its network of international multi-center clinical trials. This funding announcement not only marks a watershed moment for the company but also offers renewed hope for patients worldwide, advancing the mission to deliver breakthrough treatments that could redefine the standard of care in oncology and immunology. For more information about Duality Biologics and its pioneering work, please visit www.dualitybiologics.com.